Abstract: Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens.

Abstract: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.

Abstract: Gripping claws and pairs of arched angular profiles are arranged along the perimeter of a cylindrical surface segment so as to grip the edges of a fuselage panel, closing the opening of a pressurizable chamber.

Abstract: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.

Abstract: An immunogenic composition comprising: (i) a conjugated pneumococcal capsular saccharide; and (ii) a meningococcal factor H binding protein (fHBP) antigen, and not including meningococcal outer membrane vesicles, is useful for immunising a subject against bacterial meningitis.

Abstract: Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal saccharides. The antigens may be used in pneumococcal vaccines, but may also be used as components in vaccines for immunising against multiple pathogens.

Abstract: Pneumococcal pilus subunit RrgB has at least three clades. Serum raised against a given clade is active against pneumococci which express that RrgB clade, but is not active against strains which express one of the other two clades i.e. there is intra-clade cross-protection, but not inter-clade cross-protection. Thus an immunogenic composition can include at least two different clades of RrgB to improve strain coverage against pilus-containing pneumococci. These multiple clades may be present in the immunogenic composition as separate polypeptides or may be fused as a single polypeptide chain.

Abstract: Gripping claws and pairs of arched angular profiles are arranged along the perimeter of a cylindrical surface segment so as to grip the edges of a fuselage panel, closing the opening of a pressurizable chamber.

Abstract: A method for the preparation of molecular weight standards having peroxidase activity which can be directly identified at the time of the detection of the antigen in all western blot techniques based on the use of peroxidase.

Abstract: DNA molecules that code for IL-1 antagonists with improved biological activity arc described. DNA molecules coding for improved IL-1 antagonists inserted into expression vectors and host cells transformed with the said vectors containing the DNA coding for improved IL-1 antagonists and a method for the production of improved IL-1 antagonists in essentially pure form are also described. Preparations that can be injected or can be administered by some other route, consisting of a pharmaceutical preparation of the said mutants, are particularly useful as drugs in the field of therapy.

Abstract: A method is disclosed for the immunolocalization of epitopes of non-glucidic nature, in cellular cultures, in tissue slices, or immobilized on such supports as nitrocellulose, by means of the incubation of the sample with specific antibodies for the antigen to be immunolocalized, belonging to the class of the IgM's, and sequential treatment of concanavalin A and with an enzymatic marker capable of binding with concanavalin A, such as, e.g., peroxidase. The method comprises, before the incubation, a suitable treatment of the sample under test, e.g., with periodic acid, in order to prevent concanavalin A from binding with the carbohydrates present in the sample.